FORM FDA 3674 - FDA-3674DynSecExt04-15-2024-2-2025

Get Form
3674 form Preview on Page 1

Here's how it works

01. Edit your 3674 form online
Type text, add images, blackout confidential details, add comments, highlights and more.
02. Sign it in a few clicks
Draw your signature, type it, upload its image, or use your mobile device as a signature pad.
03. Share your form with others
Send it via email, link, or fax. You can also download it, export it or print it out.

How to use or fill out FORM FDA 3674 - FDA-3674DynSecExt04-15-2024-2 with our platform

Form edit decoration
9.5
Ease of Setup
DocHub User Ratings on G2
9.0
Ease of Use
DocHub User Ratings on G2
  1. Click ‘Get Form’ to open it in the editor.
  2. Begin by entering the 'Name of Sponsor/Applicant/Submitter' in the designated field. Ensure this matches the name on your application.
  3. Input the 'Date of the Application/Submission' accurately to reflect when you are submitting this form.
  4. Fill in your complete address, including telephone and fax numbers, ensuring all details are correct for effective communication.
  5. For product information, specify all names associated with your drug, biologic, or device. Use a continuation page if necessary.
  6. Select the type of application/submission from the provided options by checking the appropriate box.
  7. If applicable, enter any previously assigned IND/NDA/ANDA/BLA/PMA number related to your submission.
  8. In the certification section, check one of the boxes (A, B, or C) based on your compliance status regarding clinical trials.
  9. If you checked Box C, provide any National Clinical Trial (NCT) Numbers relevant to your submission.
  10. Complete the signature section by providing your name, title, and signing where indicated. Ensure all contact information is accurate.

Start using our platform today for free to streamline your form completion process!

See more FORM FDA 3674 - FDA-3674DynSecExt04-15-2024-2 versions

We've got more versions of the FORM FDA 3674 - FDA-3674DynSecExt04-15-2024-2 form. Select the right FORM FDA 3674 - FDA-3674DynSecExt04-15-2024-2 version from the list and start editing it straight away!
Versions Form popularity Fillable & printable
2024 4.3 Satisfied (26 Votes)
2023 4.3 Satisfied (20 Votes)
2019 4.6 Satisfied (55 Votes)
2012 4 Satisfied (22 Votes)
be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.
Contact us
Though FDA Form 3674 has been required for nearly all data submitted to the FDA since December 2007, it is not nearly as well recognized. The form is a notification of compliance signifying that the trials have been correctly registered and documented on clinicaltrials.gov (CT.
The June 2024 Circular provides specific labeling instructions for the administration and use of blood and blood components intended for transfusion. We believe that the June 2024 Circular will assist you in complying with labeling requirements under 21 CFR 606.122.
FDA Novel Drug Therapy Approvals for 2024 No.Drug NameApproval Date 24. Voranigo 8/6/2024 23. Leqselvi 7/25/2024 22. Kisunla 7/2/2024 21. Ohtuvayre 6/26/202446 more rows
80.3% 63.0% 83.6% 46.9% 53.1% 43.7% FDAs budget for Fiscal Year 2024 is: approximately $6.9 billion. provided by federal budget authorization (52% or $3.6 billion) and industry user fees (48% or $3.3 billion). equivalent to $10.68 per American per year.
Please submit the completed MedWatch 3500A form along with information to support the report, such as scans of labels and images of the serious adverse event, to FDA via: Email (preferred method for faster processing and reviewing): CosmeticAERS@fda.hhs.gov.
be ready to get more

Complete this form in 5 minutes or less

Get form

People also ask

In June 2024, FDA published a draft guidance titled Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.1 The requirement to submit Diversity Action Plans will apply to certain studies for which enrollment commences after 180 days from the publication of
In general, FDAs guidance documents do not establish legally enforceable responsibilities and thus are not binding on FDA or the public. Instead, guidances describe the Agencys current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.
Certificate of Compliance (CoC): It attests that the product complies with applicable laws, regulations, or industry standards, ensuring safety, quality, and environmental sustainability.